Q-omics provides the consensus-scored ITGA9-AS1 profile across patient tissues and cancer cell-line models. ITGA9-AS1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ITGA9-AS1 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, ITGA9-AS1 RNA expression shows 22,011 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KIRC, and LUAD as cancer lineages where ITGA9-AS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ITGA9-AS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ITGA9-AS1 survival associations across molecular data types. ITGA9-AS1 RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ITGA9-AS1 RNA expression–survival associations across cancer types. High ITGA9-AS1 expression shows unfavorable associations in LIHC and LGG, but favorable associations in KIRC, HNSC, UCS and THYM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ITGA9-AS1 RNA expression.
This table summarizes ITGA9-AS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ITGA9-AS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ITGA9-AS1 shows lower tumor expression in KIRC, BLCA, LUAD, COAD and KIRP and higher tumor expression in LIHC. The KIRC box plot shows higher ITGA9-AS1 RNA expression in normal versus tumor tissue (log2 FC = −0.815, t-test p < 0.001).
This table shows molecular features associated with ITGA9-AS1 in patient tissues and cancer cell lines. In patient samples, ITGA9-AS1 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set.
